Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 6274854, 11 pages
https://doi.org/10.1155/2017/6274854
Review Article

Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials

1Department of Cardiology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2Department of Cardiology, Yancheng Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng 224001, China
3Department of Traditional Chinese Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China

Correspondence should be addressed to Hua Zhou; moc.361@mhauhuohz

Received 12 January 2017; Revised 19 March 2017; Accepted 22 March 2017; Published 13 April 2017

Academic Editor: Hai-Feng Pan

Copyright © 2017 Xiaolong Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. P. Ambrosy, G. C. Fonarow, J. Butler et al., “The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries,” Journal of the American College of Cardiology, vol. 63, no. 12, pp. 1123–1133, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Špinar, J. Hradec, L. Špinarová, and J. Vítovec, “Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology,” Cor et Vasa, vol. 58, no. 5, pp. e530–e568, 2016. View at Google Scholar
  3. C. W. Yancy, M. Jessup, B. Bozkurt et al., “2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American Heart Association task force on practice guidelines,” Circulation, vol. 128, no. 16, pp. 1810–1852, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Doehner, M. Frenneaux, and S. D. Anker, “Metabolic impairment in heart failure: the myocardial and systemic perspective,” Journal of the American College of Cardiology, vol. 64, no. 13, pp. 1388–1400, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Neubauer, “The failing heart—an engine out of fuel,” New England Journal of Medicine, vol. 356, no. 11, pp. 1140–1151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Ferrari, E. Merli, G. Cicchitelli, D. Mele, A. Fucili, and C. Ceconi, “Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review,” Annals of the New York Academy of Sciences, vol. 1033, pp. 79–91, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. Chinese Society of Cardiology of Chinese Medical Association, “Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and management of chronic heart failure 2014,” Chinese Journal of Cardiology, vol. 42, no. 2, pp. 98–122, 2014 (Chinese). View at Google Scholar
  8. R. Shang, Z. Sun, and H. Li, “Effective dosing of l-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis,” BMC Cardiovascular Disorders, vol. 14, pp. 88–96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. J. DiNicolantonio, C. J. Lavie, H. Fares, A. R. Menezes, and J. H. O'Keefe, “L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis,” Mayo Clinic Proceedings, vol. 88, no. 6, pp. 544–551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. T. Higgins and S. Green, Eds., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/.
  11. J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Gürlek, E. Tutar, E. Akçil et al., “The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy,” European Journal of Heart Failure, vol. 2, no. 2, pp. 189–193, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Rizos, “Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration,” American Heart Journal, vol. 139, no. 2, pp. S120–S123, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Xi, W. Liang, J. Wu, and Z. Tan, “Clinical research of L-carnitine treatment on chronic congestive heart failure,” Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, vol. 14, no. 9, pp. 714–715, 2006 (Chinese). View at Google Scholar
  15. L. Chen and W. Ye, “Clinical research of L-carnitine treatment on sixty-two patients with chronic congestive heart failure,” China Foreign Medical Treatment, vol. 22, article 47, 2009 (Chinese). View at Google Scholar
  16. C. Lin, J. Li, J. Tang, and P. Yang, “Effects of levocarnitine among patients with chronic heart failure,” Zhejiang Practical Medicine, vol. 14, no. 2, pp. 109–110, 2009 (Chinese). View at Google Scholar
  17. A. R. Serati, M. R. Motamedi, S. Emami, P. Varedi, and M. R. Movahed, “L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms,” Cardiology, vol. 116, no. 3, pp. 178–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Ding and X. Hu, “The effectiveness of L-carnitine treatment on senile congestive heart failure,” Chinese Journal of Gerontology, vol. 32, no. 13, pp. 2881–2882, 2012 (Chinese). View at Google Scholar
  19. L. Cheng and X.-F. Tang, “Influence of levocarnitine on heart function and endocrine among patients with heart failure,” Chinese Journal of Epidemiology, vol. 34, no. 6, pp. 630–632, 2013. View at Google Scholar · View at Scopus
  20. X. Pan, “Clinical research of L-carnitine for elderly patients with chronic congestive heart failure,” Zhongguo Ji Ceng Yi Yao, vol. 21, no. 23, pp. 3550–3552, 2014 (Chinese). View at Google Scholar
  21. M. Nishimura, T. Tokoro, T. Takatani et al., “Effects of intravenous L-carnitine on myocardial fatty acid imaging in hemodialysis patients: responders or non-responders to L-carnitine,” SpringerPlus, vol. 4, pp. 353–362, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Ding and Q. Feng, “The efficiency assessment of intravenous L-carnitine on elderly patients with heart failure of coronary heart disease,” Chinese Journal of Convalescent Medicine, vol. 24, no. 7, pp. 728–729, 2015 (Chinese). View at Google Scholar
  23. L. Gao, “Clinical efficiencies of levocarnitine in the treatment of ischemic cardiomyopathy heart failure and its effect on myocardial cell function,” Journal of Bengbu Medical College, vol. 40, no. 12, pp. 1643–1645, 2015 (Chinese). View at Google Scholar
  24. J. Ma, X. Zhou, and X. Li, “The influence of L-carnitine on patients' cardiac function and renal function with resulting from chronic heart failure,” Chinese Journal of Gerontology, vol. 35, no. 20, pp. 5761–5762, 2015 (Chinese). View at Google Scholar
  25. W. Zhang, Z. Dai, J. Zhou et al., “Clinical research of L-carnitine treatment on patients of cardiorenal syndrome without hemodialysis,” Chinese Journal of Clinical Rational Drug Use, vol. 8, no. 8C, pp. 61–62, 2015 (Chinese). View at Google Scholar
  26. Z.-C. Jing, B.-X. Wu, J.-Q. Peng et al., “Effect of intravenous l-carnitine in Chinese patients with chronic heart failure,” European Heart Journal, Supplement, vol. 18, pp. A27–A36, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Wu, “The clinical effects of intravenous L-carnitine in elderly patients with heart failure of diabetes,” Xin Xue Guan Bing Fang Zhi Zhi Shi, vol. 6, pp. 84–85, 2016 (Chinese). View at Google Scholar
  28. K. Zhang, “Clinical effects and safety of intravenous L-carnitine treatment on patients of chronic heart failure,” Guide of China Medicine, vol. 14, no. 4, pp. 153–154, 2016 (Chinese). View at Google Scholar
  29. L. H. Opie, “Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium?” Lancet, vol. 353, no. 9155, pp. 768–769, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. A. P. Wong, A. Niedzwiecki, and M. Rath, “Myocardial energetics and the role of micronutrients in heart failure: a critical review,” American Journal of Cardiovascular Disease, vol. 6, no. 3, pp. 81–92, 2016. View at Google Scholar
  31. Z. T. Bloomgarden, “Obesity, hypertension, and insulin resistance,” Diabetes Care, vol. 25, no. 11, pp. 2088–2097, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. R. H. Eckel, K. Alberti, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 375, no. 9710, pp. 181–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. R. A. DeFronzo, “Pathogenesis of type 2 diabetes mellitus,” Medical Clinics of North America, vol. 88, no. 4, pp. 787–835, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. M. Katz, “Is the failing heart energy depleted?” Cardiology Clinics, vol. 16, no. 4, pp. 633–644, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. J. L. Flanagan, P. A. Simmons, J. Vehige, M. D. Willcox, and Q. Garrett, “Role of carnitine in disease,” Nutrition and Metabolism, vol. 7, article 30, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Koc, T. Ozkan, A. Z. Karabay, A. Sunguroglu, and F. Aktan, “Effect of L-carnitine on the synthesis of nitric oxide in RAW 264·7 murine macrophage cell line,” Cell Biochemistry and Function, vol. 29, no. 8, pp. 679–685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. J. Blanca, M. V. Ruiz-Armenta, S. Zambrano et al., “Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: protective role of L-carnitine,” Toxicology Letters, vol. 241, pp. 9–18, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Zambrano, A. J. Blanca, M. V. Ruiz-Armenta et al., “L-carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression,” Biochemical Pharmacology, vol. 85, no. 7, pp. 937–944, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Omori, T. Ohtani, Y. Sakata et al., “L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease,” Journal of Hypertension, vol. 30, no. 9, pp. 1834–1844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Orlandi, A. Francesconi, A. Ferlosio et al., “Propionyl-L-carnitine prevents age-related myocardial remodeling in the rabbit,” Journal of Cardiovascular Pharmacology, vol. 50, no. 2, pp. 168–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. S. G. Dzugkoev, I. V. Mozhaeva, M. A. Otiev, O. I. Margieva, and F. S. Dzugkoeva, “Effect of L-carnitine, afobazole and their combination with L-arginine on biochemical and histological indices of endothelial dysfunctions in cobalt intoxication in rats,” Patologicheskaia fiziologiia i eksperimental'naia terapiia, vol. 59, no. 2, pp. 70–75, 2015. View at Google Scholar